Archive | November, 2020
Congratulations to INVO Bioscience, Inc. on its successful offering and uplisting to The Nasdaq Capital Market.
INVO Bioscience announced the pricing of its follow-on offering raising $11.6 million. Roth Capital acted as sole book-runner for the deal. SARASOTA, Fla., Nov. 12, 2020 /PRNewswire/ — INVO Bioscience, Inc. (OTCQB: INVOD) (Nasdaq: INVO) developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, today announced the pricing of an underwritten public offering […]